Skip to main content

September 2025

Pharma Courses

Inviting applications for Technical Assistant at PGIMER

Graduate in Biological Sciences from a recognised University with two years experience from a recognized institution OR Masters degree M.Sc. Biotechnology in the Biological Sciences from a recognised university.
Walk in Drive for M.Pharm, B.Pharm in Manufacturing & Packing at Sun Pharma
Granulation, Compression, Tablet Coating, OSD Bottle Packing activities in OSD Manufacturing Plant
Syngene Hiring Synthetic & Medicinal Chemistry Scientist - Ph.D, M.Pharm, MSc Apply
Personnel handling this profile will be responsible for performing reactions as per the requirement of the project. They are also responsible for documenting the observations in relevant note books. They are to follow instructions from the supervisor and work in a group to accomplish the tasks in a timely and efficient manner.
Apprentice Program (NATS) at OneSource for M.Pharm, B.Pharm, MSc Freshers
Candidates who have completed their courses and have their Provisional Certificate (mandatory), Degree Certificate/ All Semester Marksheets ONLY considered.
Walk in Interview for M.Pharm, B.Pharm, MSc in QA, QC, Production and Packing at USV Private Limited
USV Private Limited is an Indian multinational pharmaceutical and biotechnology company in Mumbai.
Applications are now open for the Open Doors Russian Scholarship Project 2025
Must not hold a bachelors or specialist/master’s degree and must have completed or be completing a program qualifying for higher education admission in their country during the 2025-2026 academic year
Microscopic pores in brain cells may be a key to Parkinson’s
A toxic protein forms dynamic pores in the membranes of brain cells – and that may be the key to understanding how Parkinson’s disease develops. This is the conclusion of a new study from Aarhus University, where researchers have developed an advanced method to track molecular attacks in real time.
Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer
Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting.
Novartis to add pacibekitug in its cardiovascular portfolio with acquisition of Tourmaline Bio
Novartis has entered into an agreement to acquire Tourmaline Bio, Inc, a New York-based, publicly traded clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease.
Sandoz resolves patent litigation with Regeneron
Sandoz has reached an agreement with Regeneron Pharmaceuticals, Inc., to resolve all patent disputes between the two companies relating to the US Food and Drug Administration FDA-approved Sandoz aflibercept biosimilar.